Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells

Kawada, Yukina; Asahara, Shun-ichiro; Sugiura, Yumiko; Sato, Ayaka; Furubayashi, Ayuko; Kawamura, Mao; Bartolome Herranz, Alberto; Terashi-Suzuki, Emi; Takai, Tomoko; Kanno, Ayumi; Koyanagi-Kimura, Maki; Matsuda, Tomokazu; Hashimoto, Naoko; Kido, Yoshiaki

Recent studies demonstrated that insulin signaling plays important roles in the regulation of pancreatic β cell mass, the reduction of which is known to be involved in the development of diabetes. However, the mechanism underlying the alteration of insulin signaling in pancreatic β cells remains unclear. The involvement of epigenetic control in the onset of diabetes has also been reported. Thus, we analyzed the epigenetic control of insulin receptor substrate 2 (IRS2) expression in the MIN6 mouse insulinoma cell line. We found concomitant IRS2 up-regulation and enhanced insulin signaling in MIN6 cells, which resulted in an increase in cell proliferation. The H3K9 acetylation status of the Irs2 promoter was positively associated with IRS2 expression. Treatment of MIN6 cells with histone deacetylase inhibitors led to increased IRS2 expression, but this occurred in concert with low insulin signaling. We observed increased IRS2 lysine acetylation as a consequence of histone deacetylase inhibition, a modification that was coupled with a decrease in IRS2 tyrosine phosphorylation. These results suggest that insulin signaling in pancreatic β cells is regulated by histone deacetylases through two novel pathways affecting IRS2: the epigenetic control of IRS2 expression by H3K9 promoter acetylation, and the regulation of IRS2 activity through protein modification. The identification of the histone deacetylase isoform(s) involved in these mechanisms would be a valuable approach for the treatment of type 2 diabetes.


Also Published In

More About This Work

Academic Units
Published Here
February 6, 2018